These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31579445)

  • 1. Enhancing immunogenicity of novel multistage subunit vaccine of
    Khademi F; Yousefi A; Derakhshan M; Najafi A; Tafaghodi M
    Iran J Basic Med Sci; 2019 Aug; 22(8):893-900. PubMed ID: 31579445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA:DDA hybrid nanoparticles stimulates mucosal and systemic immunity.
    Khademi F; Derakhshan M; Yousefi-Avarvand A; Najafi A; Tafaghodi M
    Microb Pathog; 2018 Dec; 125():507-513. PubMed ID: 30352265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of HspX/EsxS fusion protein of Mycobacterium tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants after subcutaneous administration in animal model.
    Yousefi Avarvand A; Meshkat Z; Khademi F; Tafaghodi M
    Microb Pathog; 2021 May; 154():104842. PubMed ID: 33762199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of strong immune response against a multicomponent antigen of Mycobacterium tuberculosis in BALB/c mice using PLGA and DOTAP adjuvant.
    Khademi F; Sahebkar A; Fasihi-Ramandi M; Taheri RA
    APMIS; 2018 Jun; 126(6):509-514. PubMed ID: 29924445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the immunogenicity of a
    Yousefi Avarvand A; Meshkat Z; Khademi F; Aryan E; Sankian M; Tafaghodi M
    Iran J Basic Med Sci; 2024; 27(1):24-30. PubMed ID: 38164481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and Optimization of a New Cationic Lipid-Modified PLGA Nanoparticle as Delivery System for
    Khademi F; Yousefi-Avarvand A; Derakhshan M; Abbaspour MR; Sadri K; Tafaghodi M
    Iran J Pharm Res; 2019; 18(1):446-458. PubMed ID: 31089379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan nanoparticles containing fusion protein (Hspx-PPE44-EsxV) and resiquimod adjuvant (HPERC) as a novel booster vaccine for
    Hoseinpur R; Hasani A; Baradaran B; Abdolalizadeh J; Amini Y; Salehi R; Samadi Kafil H; Azizian K; Memar MY; Gholizadeh P; Hasani A
    J Biomater Appl; 2022 Jul; 37(1):40-47. PubMed ID: 35430919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV.
    Mansury D; Ghazvini K; Amel Jamehdar S; Badiee A; Tafaghodi M; Nikpoor AR; Amini Y; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):370-377. PubMed ID: 30691310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of multistage vaccine candidates (Mtb8.4-HspX and HspX-Mtb8.4) against Mycobacterium tuberculosis infection in mice.
    Liu W; Li J; Niu H; Lin X; Li R; Wang Y; Xin Q; Yu H; Wu Y; Zhu B; Tan J
    Int Immunopharmacol; 2017 Dec; 53():83-89. PubMed ID: 29045910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice.
    Soleimanpour S; Farsiani H; Mosavat A; Ghazvini K; Eydgahi MR; Sankian M; Sadeghian H; Meshkat Z; Rezaee SA
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10467-80. PubMed ID: 26373723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.
    Mosavat A; Soleimanpour S; Farsiani H; Sadeghian H; Ghazvini K; Sankian M; Jamehdar SA; Rezaee SA
    Infect Genet Evol; 2016 Apr; 39():163-172. PubMed ID: 26835592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
    Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.
    Agallou M; Margaroni M; Athanasiou E; Toubanaki DK; Kontonikola K; Karidi K; Kammona O; Kiparissides C; Karagouni E
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005311. PubMed ID: 28114333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dimo-thylidioctyl ammonium bromide-BCG polysaccharide nucleic acid adjuvant enhanced the immunogenicity of a Mycobacterium tuberculosis subunit vaccine].
    Song NN; Wang BX; Shi DZ; Fu LF; Luo Y; Yu HJ; Han SB; Jiao L; Qie YQ; Wang HH; Zhang Y; Zhu BD
    Zhonghua Jie He He Hu Xi Za Zhi; 2009 Jul; 32(7):513-6. PubMed ID: 19954005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological Assessment of Chitosan or Trimethyl Chitosan-Coated PLGA Nanospheres Containing Fusion Antigen as the Novel Vaccine Candidates Against Tuberculosis.
    Zare S; Kabiri M; Amini Y; Najafi A; Mohammadpour F; Ayati SH; Nikpoor AR; Tafaghodi M
    AAPS PharmSciTech; 2021 Dec; 23(1):15. PubMed ID: 34893923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
    Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B
    Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis.
    Dalirfardouei R; Tafaghodi M; Meshkat Z; Najafi A; Gholoobi A; Nabavinia MS; Sajedifar S; Meshkat M; Badiee A; Ramezani M; Varasteh AR; Naderinasab M
    Iran J Basic Med Sci; 2020 Jun; 23(6):826-832. PubMed ID: 32695300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new poly(I:C)-decorated PLGA-PEG nanoparticle promotes Mycobacterium tuberculosis fusion protein to induce comprehensive immune responses in mice intranasally.
    Du X; Tan D; Gong Y; Zhang Y; Han J; Lv W; Xie T; He P; Hou Z; Xu K; Tan J; Zhu B
    Microb Pathog; 2022 Jan; 162():105335. PubMed ID: 34861347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.